1. Home
  2. STUB vs WGS Comparison

STUB vs WGS Comparison

Compare STUB & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo StubHub Holdings Inc.

STUB

StubHub Holdings Inc.

HOLD

Current Price

$5.94

Market Cap

2.6B

ML Signal

HOLD

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$97.87

Market Cap

2.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
STUB
WGS
Founded
2000
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Retail: Computer Software & Peripheral Equipment
Sector
Consumer Discretionary
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.7B
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
STUB
WGS
Price
$5.94
$97.87
Analyst Decision
Buy
Strong Buy
Analyst Count
12
7
Target Price
$18.15
$120.71
AVG Volume (30 Days)
5.5M
487.9K
Earning Date
05-13-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.37
EPS
0.06
N/A
Revenue
$1,745,188,000.00
$427,539,000.00
Revenue This Year
$19.18
$29.98
Revenue Next Year
$19.13
$25.92
P/E Ratio
$99.17
N/A
Revenue Growth
N/A
39.97
52 Week Low
$5.74
$32.21
52 Week High
$21.49
$170.87

Technical Indicators

Market Signals
Indicator
STUB
WGS
Relative Strength Index (RSI) 31.82 64.60
Support Level $5.74 $81.58
Resistance Level $6.85 $140.83
Average True Range (ATR) 0.28 4.95
MACD 0.08 0.92
Stochastic Oscillator 16.82 68.36

Price Performance

Historical Comparison
STUB
WGS

About STUB StubHub Holdings Inc.

Stubhub Holdings Inc operates a ticketing marketplace for live events where fans can buy tickets from sellers of all types through its StubHub and viagogo websites and mobile applications. The company generates majority of its revenue from United States.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: